Samik Basu

Chief Scientific Officer • Cabaletta Bio

Dr. Samik Basu joined Cabaletta in December 2019 and was most recently Vice President of Preclinical Research and Translational Medicine before assuming his new role as Chief Scientific Officer.

Prior to joining Cabaletta, Dr. Basu was Head of Translational Sciences (Medicine) at Adaptimmune Therapeutics, Plc, where he led research efforts focused on understanding the mechanisms of resistance and response to TCR based adoptive immunotherapies to inform next generation approaches and clinical strategies. Before that, Dr. Basu co-led preclinical development efforts for Keytruda (pembrolizumab) at Merck Research Laboratories.

He is a physician-scientist with 17 years of industry and academic experience in adoptive immunotherapy, translational research, autoimmunity, and tumor immunology with prior roles at the National Institutes of Health, Albert Einstein College of Medicine, and the University of Pennsylvania. Dr. Basu received his M.D. from Temple University and completed residency training in Clinical Pathology.

Also Speaking

Stephen Ward

Chief Manufacturing Officer • Cell and Gene Therapy Catapult

Andrew Moreo

Head of Process Development • Andelyn Biosciences

Stefanos Theoharis

Core Team Member • Cell One Partners

Event Info


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.